×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
PR Newswire
Kazia CEO Dr. John Friend said: "We are pleased to announce we have exclusively licensed the development, manufacture and commercialization of...
2 months ago
Kazia concludes first stage of Phase I cancer treatment trial
Clinical Trials Arena
Kazia Therapeutics has announced the successful completion of the first stage of the Phase I trial of EVT801 in patients with advanced...
3 weeks ago
Kazia stops paxalisib brain cancer trial early on promising data
BioWorld MedTech
Kazia Therapeutics Ltd. stopped its two-part paxalisib plus radiotherapy phase I trial early based on positive safety and promising clinical...
3 months ago
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED ...
PR Newswire
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has...
3 weeks ago
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More ...
Yahoo Life UK
Those following along with Kazia Therapeutics Limited ( ASX:KZA ) will no doubt be intrigued by the recent purchase of...
2 weeks ago
Kazia Provides Overview of Paxalisib Related Presentations From the Society of Neuro-Oncology 2023 Annual Meeting
BioSpace
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of...
6 months ago
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
PR Newswire
SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today...
3 months ago
Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
Yahoo Movies UK
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
2 weeks ago
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
PR Newswire
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an.
5 months ago
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
PR Newswire
The deficiency notification has no immediate impact on the company's operations or listing. Kazia's securities will continue to trade as normal...
6 months ago